[Brief Introduction of Seminar]

This session provides an overview of China's pharmaceutical and biotechnology market, key industry trends, and emerging partnership opportunities. Participants will gain insights into licensing, strategic collaborations, and cross-border business development, supported by real-world global partnering and commercialization success cases.

​

[Brief Introduction of Speaker]

Mr. Zheng is the Managing Partner of YAFO Capital. He has been focusing on cross-border investment in healthcare sector since the beginning of his career life. Mr. Zheng has been involved in 30+ global life science BD transactions and advisory assignments and has led the team to close numerous deals. Before joining YAFO Capital, He was an equity research analyst covering the pharmaceutical and medical device sectors at Roth Capital Partners, a full-service investment banking firm headquartered in California. Mr. Zheng received a MS in Finance from Vanderbilt University in the US and a BS in Finance from the University of International Business and Economics in Beijing.​

[Brief Introduction of Seminar]

This session will provide an introduction to the Pharmaceutical Supply Chain Initiative (PSCI), highlighting our mission, global impact, commitment, and collaborative efforts to advance responsible pharmaceutical supply chains. Attendees will also hear from a leading Korean company as it shares its experience of partnering with PSCI, demonstrating how collaboration, capability building, and shared best practices have supported its sustainability journey and continuous improvement.​

[Brief Introduction of Speaker]

James Choi is Executive Vice President, Chief Marketing Officer and Head of Sales Support, Project Management, and Global Public Affairs at Samsung Biologics.

Mr. Choi holds a bachelor's degree in Mechanical Engineering from the University of California, Irvine, and an MBA from the University of Southern California.  

[Brief Introduction of Seminar]

This session will provide an introduction to the Pharmaceutical Supply Chain Initiative (PSCI), highlighting our mission, global impact, commitment, and collaborative efforts to advance responsible pharmaceutical supply chains. Attendees will also hear from a leading Korean company as it shares its experience of partnering with PSCI, demonstrating how collaboration, capability building, and shared best practices have supported its sustainability journey and continuous improvement.​

[Brief Introduction of Speaker]

Hello, my name is Hyungseok Kim, and I am a GFE Manager at Boehringer Ingelheim Korea. I am responsible for Environment, Health & Safety (EHS) and Security, ensuring that our employees can work in a safe, healthy, and secure workplace.​

​[Brief Introduction of Seminar]

Latest Policy Directions and Operational Status of the Customized Functional Food System, along with Safety Management and System Understanding Across the Entire Process—From Consumer-Tailored Consultation to Subdivision, Combination, and Sales​​​

[Brief Introduction of Speaker]

I work in the Health Functional Food Policy Division, Food Safety Policy Bureau, Ministry of Food and Drug Safety (MFDS), where I am responsible for safety management of health functional foods, including personalized health functional foods. 

​[Brief Introduction of Seminar]

○ Assess the Need for Personalized Health Functional Foods and Future Development Directions from Government, Industry, and Consumer Perspectives

○ Expected Benefits of Personalized Health Functional Foods for Key Stakeholders

○ Market and Business Strategies to Advance the Personalized Health Functional Food Ecosystem 

[Brief Introduction of Speaker]

​I am a Principal Engineer on the Development Team at Tobecon, with approximately 14 years of experience in app and web development. I am currently responsible for development of the Pillgram service. 

At this seminar, I will present on "Why Personalized Health Functional Foods Matter to Government, Consumers, and Industry — and the Way Forward," drawing on hands-on experience building personalized health-supplement services to outline the direction the industry needs to take. 

 [Brief Introduction of Seminar]

○ Market Changes, Service Utilization, and Regulatory Measures Following the Implementation of the Personalized Health Functional Food System

○ Health Functional Food Market Trends and Key Industry Changes Since Implementation

○ Consumer Service Utilization and Measures to Enhance Safety and Trust​ 

[Brief Introduction of Speaker]

Eungyo Jang is a Researcher at the Policy Research Office of the Korea Consumer Agency (KCA). Her work focuses on consumer policy and market analysis, with an emphasis on market trends and changes in the consumer environment from a consumer perspective.

[Brief Introduction of Seminar]

Introduction to TIPS program, the Ministry of SMEs and Startups' flagship support program for tech startups. Covers the program's background and operating structure, along with how to apply and what support is provided. 

[Brief Introduction of Speaker]

Manages the TIPS program at the Korea Angel Investment Association. 

[Brief Introduction of Seminar]

This session covers the structure and key benefits of SCALEUP TIPS. It highlights the requirements biotech companies must meet to secure the Investment-Linked R&D Program, and shares success cases from selected biotech companies to illustrate effective follow-on scale-up strategies. 

[Brief Introduction of Speaker]

Changyeon Lee began his career working on government-funded international joint R&D programs, including technology transfer and commercialization. He went on to manage government-funded startup support programs (Early-Stage Startup Package among others) and R&D programs (TIPS and SCALEUP TIPS). He currently oversees the planning and operation of SCALEUP TIPS and other follow-on support programs at KVCA.  

[Brief Introduction of Seminar]

At this conference, I will introduce global trends in AI-driven drug discovery and the latest market developments, while providing a comprehensive overview of how AI is being applied across the entire drug development lifecycle. 

[Brief Introduction of Speaker]

My work spans both academia and industry, allowing me to bridge these two sectors with a deep understanding of scientific research and translational drug development. In academia, my research primarily focuses on the application of AI and bioinformatics to precision medicine and genomics across a range of disease contexts. On the industry side, I co-founded UPPThera, a drug development company leveraging targeted protein degradation technology.